Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis ...

Tremfya is the first and only fully-human, dual-acting IL-23p19 subunit inhibitor approved in both ulcerative colitis and ...

As the only IL-23 treatment to show significant inhibition of structural damage, TREMFYA equips healthcare providers with critical data so their patients do not have to compromise their future ...

Tremfya (guselkumab) is a prescription drug that’s used to treat certain inflammatory conditions, such as psoriatic arthritis. Tremfya comes as a liquid solution for injection. If you’d like ...

"Data from the ASTRO study demonstrate that subcutaneous induction treatment with TREMFYA provides clinically meaningful remission in patients with ulcerative colitis, similar to the effects seen ...

Guselkumab is the first IL-23 inhibitor approved for Crohn's disease with subcutaneous and intravenous options, targeting inflammation by blocking IL-23 and binding to CD64. The GRAVITI study ...

TREMFYA ® demonstrated clinically meaningful ... Findings for dual-acting are limited to in vitro studies that demonstrate guselkumab binds to CD64, which is expressed on the surface of IL ...

"These results highlight the potential of TREMFYA to redefine ulcerative colitis care with a fully subcutaneous induction and maintenance regimen that offers a convenient option with meaningful ...